Unopposed estrogen therapy and the risk of invasive breast cancer

Wendy Y. Chen, Jo Ann E. Manson, Susan E. Hankinson, Bernard Rosner, Michelle D. Holmes, Walter C. Willett, Graham A. Colditz

Research output: Contribution to journalArticlepeer-review

220 Scopus citations

Abstract

Background: Although short-term unopposed estrogen use does not seem to increase breast cancer risk, the effect of longer-term estrogen use remains unclear. We sought to assess the relationship between longer-term use of unopposed estrogen and the risk of invasive breast cancer over an extended follow-up period. Methods: Within the Nurses' Health Study, a prospective cohort study, we observed 11 508 postmenopausal women who had a hysterectomy and reported information on estrogen use at baseline (1980). The study population was expanded every 2 years to include women who subsequently became postmenopausal and had a hysterectomy, so that 28 835 women were included in the final follow-up period (2000-2002). Estrogen use was assessed from self-reported data on biennial questionnaires. The main outcome was invasive breast cancer. Results: A total of 934 invasive breast cancers were included in the analysis. Breast cancer risk increased with duration of unopposed estrogen use among longer-term users with the highest risk seen in cancers positive for estrogen receptor (ER+) and progesterone receptor (PR+). The multivariate relative risks (RRs) and 95% confidence intervals (CIs) for breast cancer with current use of unopposed estrogen for less than 5 years, 5 to 9.9 years, 10 to 14.9 years, 15 to 19.9 years, and 20 years or longer were, respectively, 0.96 (95% CI, 0.75-1.22), 0.90 (95% CI, 0.73-1.12), 1.06 (95% CI, 0.87-1.30), 1.18 (95% CI, 0.95-1.48), and 1.42 (95% CI, 1.13-1.77) (P for trend <.001). The risk of ER+/PR+ breast cancers was noted to be statistically significant after 15 years of current use (RR, 1.48; 95% CI, 1.05-2.07). Conclusion: Users of unopposed estrogen were at increased risk of breast cancer but only after longerterm use.

Original languageEnglish
Pages (from-to)1027-1032
Number of pages6
JournalArchives of internal medicine
Volume166
Issue number9
DOIs
StatePublished - May 8 2006

Fingerprint

Dive into the research topics of 'Unopposed estrogen therapy and the risk of invasive breast cancer'. Together they form a unique fingerprint.

Cite this